PMID- 30468474
OWN - NLM
STAT- MEDLINE
DCOM- 20200113
LR  - 20200113
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 22
IP  - 21
DP  - 2018 Nov
TI  - A combination of mRNA expression profile and miRNA expression profile identifies 
      detection biomarkers in different tumor stages of laryngeal squamous cell 
      carcinoma.
PG  - 7296-7304
LID - 16266 [pii]
LID - 10.26355/eurrev_201811_16266 [doi]
AB  - OBJECTIVE: This study was conducted to investigate microRNA (miRNA) target 
      regulations during the disease progression in laryngeal squamous cell carcinoma 
      (LSCC) and identify biomarkers in different tumor stages. MATERIALS AND METHODS: 
      The mRNA dataset GSE59102 and miRNA dataset GSE70289 were used in this study. 
      After pretreatment, differentially expressed genes/miRNAs (DEGs/DEMs) in 
      different tumor stages (beginning vs. margin, advanced vs. margin, and beginning 
      vs. advanced) were selected on the basis of their limma package. Then, the 
      enrichment analysis for these DEGs was conducted using ClueGO. Protein-protein 
      interaction (PPI) network analysis was performed on the basis of the BioGRID 
      database. After prediction of target genes of DEMs according to three validated 
      miRNA databases, an integrated miRNA target network and its pathways were drawn 
      using the multiMiR package. RESULTS: Numerous DEGs were identified in different 
      tumor stages of LSCC (beginning vs. margin, advanced vs. margin, and beginning 
      vs. advanced), and a set of 18 DEMs was identified. Cell cycle was the most 
      significantly enriched pathway of the DEGs. Four hub nodes (MCM2, EGFR, CDK2, and 
      CDK1) were highlighted in the PPI network. In the integrated miRNA target 
      network, 2 miRNAs were predominant: hsa-miR-331-3p (2 predicted targets, E2F1 and 
      TNFRSF10B) and has-miR-375 (1 predicted target, TNNI3). These genes were tied up 
      with cell cycle or apoptosis pathway. CONCLUSIONS: Several genes and miRNAs might 
      be used as markers for LSCC in different tumor stages (e.g., MCM2, EGFR, CDK1, 
      CDK2, hsa-miR-331-3p, hsa-miR-375). They might function through the involvement 
      of the cell cycle pathway.
FAU - Yu, C-H
AU  - Yu CH
AD  - Department of Otolaryngology, Daqing Oilfield General Hospital, Daqing, 
      Heilongjiang, China. liyunchuan1964@163.com.
FAU - Xing, F-Y
AU  - Xing FY
FAU - Zhang, J-Y
AU  - Zhang JY
FAU - Xu, J-Q
AU  - Xu JQ
FAU - Li, Y-C
AU  - Li YC
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Databases, Genetic
MH  - Gene Expression Profiling
MH  - Gene Regulatory Networks
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - MicroRNAs/*genetics
MH  - Neoplasm Staging
MH  - RNA, Messenger/*genetics
MH  - Squamous Cell Carcinoma of Head and Neck/*genetics/pathology
MH  - *Transcriptome
EDAT- 2018/11/24 06:00
MHDA- 2020/01/14 06:00
CRDT- 2018/11/24 06:00
PHST- 2018/11/24 06:00 [entrez]
PHST- 2018/11/24 06:00 [pubmed]
PHST- 2020/01/14 06:00 [medline]
AID - 16266 [pii]
AID - 10.26355/eurrev_201811_16266 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7296-7304. doi: 
      10.26355/eurrev_201811_16266.